logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
J

Juan P. Frías

los angeles institute for metabolic research
H指数:63
被引数:2.2万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Petrelintide, a human amylin analogue for the treatment of obesity (ZUPREME 1): a randomised, double-blind, placebo-controlled, phase 2 trial

Petrelintide，一种用于治疗肥胖的人类胰淀素类似物（ZUPREME 1）：一项随机、双盲、安慰剂对照的2期临床试验

Lancet Diabetes & Endocrinology
IF41.8
2026-09-290
PRE
W Timothy Garvey; Jamy Ard; Lisa Connery; Juan Pablo Frias; Carel W le Roux; Kirsi H Pietiläinen; Maj Dinesen; Berith F Hagen; Louise Larsen; Dan Hesse; David M Kendall
Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity

CT-388（一种每周一次的选择性GLP-1/GIP受体激动剂）对预临床模型和肥胖受试者中体重减轻及血糖控制的效应

Molecular Metabolism
IF6.6
2025-11-280
OAAI
Manu V. Chakravarthy; Ruben Rodriguez; Anne Hergarden; Michael A. Elliott; Juan P. Frias; Federico A. Argüelles-Tello; Edgar Tenorio; Jonathan E. Rankin; Jingtao Wu; Shyam Krishnan; Daniel A. Erlanson; Raymond V. Fucini; Derek Bone; Jeffrey S. Iwig; Luis Acosta; Ashley Untereiner; Asmita Pant; Avalon Patton; Leyla L. Sanchez-Sanchez; Jian Luo
Clinical trial: A Phase 2 Randomised Platform Study to Assess Monotherapy and Combination Treatment Regimens in Metabolic Dysfunction-Associated Steatohepatitis

临床试验：一项评估代谢功能障碍相关脂肪性肝炎单药疗法和联合治疗方案的第2期随机平台研究

ALIMENTARY PHARMACOLOGY & THERAPEUTICS
IF6.7
2025-11-012
OA
Frias, Juan; Schmouder, Robert; Lawitz, Eric; Zhang, Yiming; Zhou, Heng; Badman, Michael K.; Ukomadu, Chinweike; Weiss, H. Markus; Zack, Julia; Yadav, Brijesh; Martic, Miljen; Drakeford, Clive; Koo, Phillip; Naoumov, Nikolai V.; Greenbaum, Linda E.
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial

代谢功能障碍相关脂肪性肝炎（HARMONY）中，每周一次efruxifermin相较于安慰剂的疗效与安全性：一项多中心、随机、双盲、安慰剂对照、2b期试验的96周结果

lancet
IF0
2025-08-140
PRE
Mazen Noureddin; Juan P Frias; Guy W Neff; K Jean Lucas; Cynthia Behling; Pierre Bedossa; Julie Dubourg; Doreen Chan; Mark Burch; Erica Fong; Brittany de Temple; Matt Minerva; Kim Barrett; Reshma Shringarpure; Erik J Tillman; Timothy Rolph; Andrew Cheng; Kitty Yale
Efficacy and safety of CT-868, a novel, fully biased, dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double-blind, randomized placebo controlled phase 2 trial

CT-868（一种新型、完全偏向性、双重胰高血糖素样肽-1/葡萄糖依赖性促胰岛素多肽受体激动剂）在2型糖尿病中的疗效与安全性：一项双盲、随机安慰剂对照2期临床试验

diabetes obesity metabolism
IF0
2025-08-050
OAAI
Manu V. Chakravarthy MD; Michael A. Elliott MA; Luis Acosta BA; Gabriele E. Sonnenberg MD; Damian Bialonczyk PharmD; Jingtao Wu PhD; Federico A. Argüelles-Tello MD; Raymundo Garcia-Reza MD; José Gerardo González-González MD; Stig K. Hansen PhD; Juan P. Frias MD
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo- controlled, phase 2b trial
LANCET GASTROENTEROLOGY & HEPATOLOGY
IF38.6
2023-12-0144
PRE
Harrison, Stephen A.; Frias, Juan P.; Neff, Guy; Abrams, Gary A.; Lucas, K. Jean; Sanchez, William; Gogia, Sudhanshu; Sheikh, Muhammed Y.; Behling, Cynthia; Bedossa, Pierre; Shao, Lan; Chan, Doreen; Fong, Erica; de Temple, Brittany; Shringarpure, Reshma; Tillman, Erik J.; Rolph, Timothy; Cheng, Andrew; Yale, Kitty

研究方向

暂未获取到该数据
J
Julio Rosenstock
H 指数:120论文数:696被引数:6.7万
V
Vanita R. Aroda
H 指数:69论文数:382被引数:2.3万
S
Stephen A. Harrison
H 指数:116论文数:775被引数:6.6万
M
Melanie J. Davies
H 指数:132论文数:1,562被引数:9.1万
A
Axel Haupt
H 指数:44论文数:189被引数:1.0万
Z
Zvonko Miličević
H 指数:29论文数:204被引数:6,202
S
Serge Jabbour
H 指数:35论文数:158被引数:5,318
C
Cristian Guja
H 指数:29论文数:168被引数:7,878
L
Laura Fernández Landó
H 指数:20论文数:76被引数:4,732
E
Elise Hardy
H 指数:18论文数:89被引数:1,756